Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00456599 · ClinicalTrials.gov registry record · Phase 2
Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
NCT00456599 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 71 participants.
The verdict
NCT00456599, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
Study Summary
This study will examine a sequence of treatments including pre-operative chemotherapy and radiation, surgery and post-operative chemotherapy for resectable pancreatic cancer.
Interventions
- DRUG oxaliplatin
- DRUG gemcitabine
- PROCEDURE Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2007-04 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00456599
The ClinicalTrials.gov registry entry for NCT00456599 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which oxaliplatin is the first listed.
NCT00456599 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00456599 about?
NCT00456599 is a clinical study titled "Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer". This study will examine a sequence of treatments including pre-operative chemotherapy and radiation, surgery and post-operative chemotherapy for resectable pancreatic cancer.
What is the current status of trial NCT00456599?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2007-04. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00456599?
The interventions under investigation include: oxaliplatin (DRUG), gemcitabine (DRUG), Radiation (PROCEDURE).
Who is sponsoring clinical trial NCT00456599?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.